PUBLISHER: Grand View Research | PRODUCT CODE: 1530036
PUBLISHER: Grand View Research | PRODUCT CODE: 1530036
The global on-body injectors market size is expected to reach USD 12.7 billion by 2030, registering a CAGR of 14.9% from 2024 to 2030, according to a new report by Grand View Research, Inc. The on-body injectors increase patient adherence to medication by offering easy-to-use, less pain and enabling extended drug administration without frequent hospital visits. These advantages of on-body injectors are significantly increasing their popularity. Moreover, regions such as Asia Pacific, with developing healthcare infrastructure and rising adoption of advanced medical devices, offer huge opportunities for market growth over the forecast period.
The increasing concerns over needle stick injuries and the need to increase the safety for both patients and healthcare professionals by eliminating risks associated with needle insertion, drug preparation, and covering & disposing of needles, coupled with the increasing prevalence of chronic diseases such as cancer are some of the factors expected to drive the market growth over the forecast period.
According to the WHO agency International Agency for Research on Cancer (IARC), around 20 million people were diagnosed with cancer, and around 9.7 million mortalities occurred due to cancer in 2022. Several cancers and other chronic disease treatments require frequent injections of medications over extended periods. On-body injectors offer a convenient and potentially less disruptive alternative for patients to receive these medications compared to traditional hospital visits or self-administered injections, which can significantly increase their demand over the forecast period.